The Effects of SCH 351125 [ancriviroc] on Mononuclear Cell Trafficking to Joints, Synovial Inflammation and Expression of Chemokines in Subjects With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2016
At a glance
- Drugs Ancriviroc (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Schering-Plough
- 14 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 17 Aug 2013 New source identified and integrated (ISRCTN: Current Controlled Trials: 87502236)
- 24 Jul 2007 New trial record.